InvestorsHub Logo
Followers 18
Posts 899
Boards Moderated 0
Alias Born 11/19/2010

Re: AA_610 post# 6239

Wednesday, 03/19/2014 11:16:15 AM

Wednesday, March 19, 2014 11:16:15 AM

Post# of 106837
After FDA approval and commercialization, I think $10 is definitely possible.

I believe with positive news on the phase 3 Myocell trials, we'll surpass 0.10 . Factor in further positive 12-month results from the phase 1 Angel trial, mixed with actual revenue from both recent partnerships and international training programs, I would expect to see higher.

Financials showing enough revenue to have cleared off debt, cover all expenses including trial expenses, and maybe a little left for profit, I would expect 0.50+.

The FDA is only for the American market. That would be huge because it proves without a shadow of a doubt the effectiveness of BioHeart's product.
But the medical tourism sector is HUGE.

With the recent partnerships, international revenue could be quite significant, considering the $BILLIONS that are already spent on treatments, and that BioHeart's treatments are proving to be far more effective.

This wasn't always a "penny stock" and I'm confident enough to say I'll ride this into BHRT being worth a few dollars per share again. We're not far off from key mile stones, and we seem to be accomplishing goals and then some at an aggressive and impressive pace.

My honest opinions.